`
The global diabetes treatment devices market size was valued at USD 10.83 billion in 2018 and is projected to reach USD 22.83 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.5% over the forecast period. This steady expansion reflects the mounting global burden of diabetes and the increasing demand for technologically advanced, minimally invasive insulin delivery solutions.
Diabetes remains one of the most prevalent chronic diseases worldwide, classified into Type 1 and Type 2. According to the International Diabetes Federation, approximately 425 million adults were living with diabetes in 2017, and this number is projected to surge to nearly 629 million by 2045. The scale of this health challenge forms the foundation of a rapidly growing market for treatment devices.
Key Market Drivers
Rising Global Prevalence of Diabetes Rapid urbanization, sedentary lifestyles, and growing obesity rates — particularly in developing economies — are major contributors to increasing diabetes incidence. Countries including China, India, the United States, Brazil, and Mexico collectively account for an estimated 55–60% of the global diabetic population. China and India alone represent around 44% of this burden. The World Health Organization reported approximately 1.9 billion overweight adults globally in 2016, with 650 million classified as obese — a key risk factor for Type 2 diabetes.
Innovation in Insulin Delivery Devices A critical growth driver is sustained investment in research and development of novel, minimally invasive insulin delivery technologies. Artificial pancreas systems — which integrate insulin pumps with continuous glucose monitoring — represent a significant leap in diabetes management. In February 2019, Tandem Diabetes Care received FDA approval for the t:Slim X2, the first interoperable insulin pump cleared for both children and adults. The same year, Bigfoot Biomedical partnered with Eli Lilly to develop AI-powered insulin dosing solutions, underscoring the industry's shift toward smart, data-driven care.
Public-Private Collaboration Partnerships between governments, healthcare institutions, and private companies are accelerating product development and distribution, further fueling market growth globally.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-treatment-devices-market-100777
Market Segmentation
By Product The market is segmented into insulin pens, insulin pumps, insulin jet injectors, insulin syringes, and others. Insulin pens hold the dominant share, driven by their user-friendly, prefilled, and reusable design — increasingly preferred over traditional syringes. Insulin pumps are the fastest-growing sub-segment due to their ability to continuously infuse insulin, making them particularly valuable for the expanding Type 1 diabetes patient pool.
By Distribution Channel The market is divided into retail sales and institutional sales. Retail sales lead the distribution landscape, propelled by the growing penetration of private-label brands in retail pharmacies at competitive prices. Key partnerships, such as AgaMatrix and Perrigo's collaboration which made blood glucose monitors available across 15,000+ U.S. retail pharmacies, highlight the strength of this channel. Institutional sales — through hospitals and clinics — remain significant, especially for monitoring non-diabetic hospitalized patients at risk of glycemic complications.
Regional Analysis
North America dominates the market, generating USD 4.38 billion in 2018 and holding a 40.44% market share, driven by strong R&D investment, FDA approvals, and high adoption of advanced insulin delivery technologies.
Asia Pacific is the fastest-growing region, fueled by a vast and growing diabetic population — over 60% of global diabetes cases reside in Asia. Rising awareness, expanding healthcare infrastructure, and demand for minimally invasive devices are key catalysts.
Europe shows steady growth supported by government-led awareness campaigns for early diabetes diagnosis and treatment adoption. Latin America and Middle East & Africa are emerging markets showing meaningful growth potential, supported by rising healthcare expenditure and increasing disease awareness.
Competitive Landscape
The market features several dominant players with robust product portfolios and global distribution networks:
- F. Hoffmann-La Roche Ltd — launched the Accu-Chek Instant system (March 2021) and partnered with BIOCORP for smart insulin pens in France (April 2021)
- Medtronic — a market leader, announced the acquisition of Companion Medical (August 2020), maker of the InPen FDA-approved smart insulin pen system
- Novo Nordisk A/S — a leading force in insulin and delivery innovation
- Tandem Diabetes Care — notable for its FDA-cleared interoperable pump technology
- Abbott — partnered with Tandem (June 2020) to integrate continuous glucose monitoring with insulin delivery systems
- Others include BD, Eli Lilly, Sanofi, and B. Braun Melsungen AG
Conclusion
The global diabetes treatment devices market stands at an inflection point. With no universal cure for diabetes available, insulin therapy and its delivery mechanisms remain central to patient care. The convergence of AI, miniaturization, and interoperability is transforming devices from basic tools into intelligent health management systems. With a projected market value of nearly USD 22.83 billion by 2032, this sector presents compelling opportunities for stakeholders across healthcare, technology, and investment landscapes.
`
Top comments (0)